Papaverine

5 interactions on record

Papaverine has 5 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carbidopa And Levodopa, Carbidopa, Levodopa And Entacapone, Carbidopa. Patients taking Papaverine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 5
Major: 2
Moderate: 3

Major (2)

Papaverine + Carbidopa And Levodopa— The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by papaverine.
Papaverine + Carbidopa, Levodopa And Entacapone— Beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by papaverine.

Moderate (3)

Papaverine + Carbidopa— Beneficial effects of levodopa in Parkinson's disease reported to be reversed; patients should be carefully observed for…
Papaverine + Carbidopa Tablets— Beneficial effects of levodopa in Parkinson's disease may be reversed; patients should be carefully observed for loss of…
Papaverine + Foscarbidopa/Foslevodopa— Dopamine D2 receptor antagonist may reduce effectiveness of foslevodopa. Monitor for worsening Parkinson's symptoms.

Papaverine + Carbidopa And Levodopa⚠️Major

The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by papaverine.

Papaverine + Carbidopa, Levodopa And Entacapone⚠️Major

Beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by papaverine.

Papaverine + Carbidopa🟡Moderate

Beneficial effects of levodopa in Parkinson's disease reported to be reversed; patients should be carefully observed for loss of therapeutic response.

Papaverine + Carbidopa Tablets🟡Moderate

Beneficial effects of levodopa in Parkinson's disease may be reversed; patients should be carefully observed for loss of therapeutic response.

Papaverine + Foscarbidopa/Foslevodopa🟡Moderate

Dopamine D2 receptor antagonist may reduce effectiveness of foslevodopa. Monitor for worsening Parkinson's symptoms.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.